RxActuator names seven-member clinical advisory board for veterinary home infusion

RxActuator has launched its first Clinical Advisory Board to guide protocol development, education and validation for its wearable Mini-Infuser platform. The move comes as veterinary practices face staffing and cost pressures that are pushing more care into the home. Why it matters: - RxActuator is trying to make outpatient continuous-rate infusion a practical option for more veterinary patients. - The company is positioning home-based infusion as a way to reduce hospital stays, lower costs for pet owners and ease ICU pressure at specialty clinics. - The advisory board adds specialty credibility as RxActuator pushes for broader adoption of its wearable drug infusion platform. What happened: - Journey Actuating Technologies, Inc., doing business as RxActuator, announced its inaugural seven-member Clinical Advisory Board on June 17, 2026. - The board is built to support veterinary “Hospital-at-Home” care for companion animals using the RxActuator Mini-Infuser. - Jeff Journey, CEO of Journey Actuating Technologies, said the board’s expertise will help accelerate protocol adoption and strengthen the company’s evidence base. - Dr. James Gaynor will chair the advisory board. The details: - The board will guide clinical protocol development, post-market validation, peer-reviewed publication and continuing veterinary education. - Advisors will represent RxActuator at specialty conferences including ACVS, IVECCS, ACVAA, IVAPM, ACVIM, the Veterinary Cancer Society, IAAHPC and AAEP. - Members cover pain management, anesthesiology, pharmacology, internal medicine, rehabilitation, oncology, palliative care and equine surgery. - Founding members include James Gaynor, Mark Papich, Tyler Carmack, Harry Cridge, Lindsey Fry, Greg Staller and Luke Wittenburg. - Gaynor is a pain management and anesthesiology specialist and former Section Chief of Anesthesiology at Colorado State University. - Papich is a professor of clinical pharmacology at NC State University and a former president of the American College of Veterinary Clinical Pharmacology. - Carmack leads hospice and palliative care at Caring Pathways and founded Hampton Roads Veterinary Hospice in 2011. - Cridge is a small animal internal medicine specialist focused on gastrointestinal and pancreatic disease. - Fry is a veterinary sports medicine and rehabilitation specialist focused on chronic and palliative pain protocols. - Staller is an equine surgeon and owner of Running ‘S’ Equine Veterinary Services. - Wittenburg is a UC Davis professor leading NIH-funded research on anticancer drug pharmacology and comparative oncology. - The company says Dr. Gaynor used the RxActuator pump first in his own dog and then in acute and chronic pain patients for years. - RxActuator cites a 2025 Journal of Veterinary Internal Medicine study on outpatient pancreatitis care using the Mini-Infuser that showed an 89.5% treatment success rate and substantial cost savings. - The company says the Mini-Infuser delivered continuous antibiotic and antifungal therapy in a recent equine ophthalmic case after corneal lesion repair. Between the lines: - The timing reflects a broader shift in veterinary care as staffing shortages, rising costs and client financial concerns make home-based treatment more appealing. - RxActuator is using clinical advisors to support both medical legitimacy and market adoption. - The board also helps the company expand beyond pain management into oncology, palliative care and equine applications. - The company is leaning on published studies and real-world use cases to frame the Mini-Infuser as a proven platform rather than a new device concept. What’s next: - RxActuator said the board will help build evidence for broader adoption of wearable, at-home CRI. - The company plans to use the advisory board for education, publication and protocol development across specialty channels. - RxActuator is also developing intelligent infusion technology tied to real-world clinical outcomes. - The company is executing a Seed+ raise ahead of a targeted Series A. - RxActuator’s LinkedIn page is available here .